Biological approach to treating OCD

0.0(0)
studied byStudied by 0 people
learnLearn
examPractice Test
spaced repetitionSpaced Repetition
heart puzzleMatch
flashcardsFlashcards
Card Sorting

1/10

encourage image

There's no tags or description

Looks like no tags are added yet.

Study Analytics
Name
Mastery
Learn
Test
Matching
Spaced

No study sessions yet.

11 Terms

1
New cards

antidepressants

affects levels of neurotransmitters including serotonin

2
New cards

SSRIs

increases level of serotonin at the synapse by preventing reuptake. fluoxetine is an example

3
New cards

combination treatment

SSRIs combined with psychological therapies like CBT and with other drugs

4
New cards

alternative to SSRIs

clomipramine and SNRIs

5
New cards

SNRIs

serotonin and noradrenaline reuptake inhibitors. different class of antidepressants, increases levels of serotonin and noradrenaline

6
New cards

clomipramine - tricylic antidepressant

acts on systems including the serotonin system and works in the same way as SSRIs. however it has more severe side affects

7
New cards

research support for biological treatments for OCD - soomro et al

reviewed 17 studies comparing SSRIs to placebos in treating OCD. all studies showed significantly better outcomes in SSRIs compared to placebos.

8
New cards

research support - nestadt, review of twins

68% of MZ twins share OCD compared to 31% of DZ twins. supports the genetic explanation of OCD

9
New cards

strength of biological treatments for OCD - cost-effective and non-disruptive

drugs are cheap compared to psychological treatments and they're not disruptive to people's lives like therapy sessions are

10
New cards

limitation of biological treatments for OCD - serious side effects

these drugs can cause side effects like indigestion and blurred vision. this is particularly prominent in the tricyclic clomipramine

11
New cards

limitation of biological treatments for OCD - bias in evidence

some psychologists believe there is bias in evidence as researchers are often sponsored by drug companies that may selectively publish positive outcomes.